PRODUCT LITERATURE

Fondaparinux: A Pharmacoeconomic Review of its Use in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome

---

In OASIS-5, a large pivotal trial in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), subcutaneous fondaparinux 2.5 mg once daily was noninferior to subcutaneous enoxaparin 1mg/kg twice daily (both agents were administered over a mean of about 5 days in combination with antiplatelet therapy) in reducing death or ischaemic events at 9 days, and the efficacy was maintained for up to 6 months (study end). However, fondaparinux was associated with a significantly lower rate of bleeding than enoxaparin in the first 9 days, and at 3 and 6 months. This lower rate of bleeding led to lower longterm mortality and morbidity with fondaparinux than with enoxaparin.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Diviti
Acute Coronary Syndrome

Specific Detail Info

Pharmacoeconomics 2010; 28 (8): 687-698

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment